A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

被引：2
|
作者：
Sun, Mingyuan [1 ]
Qi, Junyuan [1 ]
Chen, Zi [2 ]
Zhang, Hongli [2 ]
Song, Yongping [3 ]
Shen, Aizong [4 ]
Liu, Huilan [4 ]
Huang, Jianying [5 ]
Zhou, Fuling [5 ]
Jin, Jie [6 ]
Lu, Ming [7 ]
Ahmad, Mohammad [7 ]
Men, Lichuang [2 ]
Cen, Wan [2 ]
Yang, Dajun [2 ,8 ]
Wang, Jianxiang [1 ]
Zhai, Yifan [2 ,7 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] USTC Anhui Prov Hosp, Affiliated Hosp 1, Hefei, Peoples R China
[5] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[7] Ascentage Pharma Grp Inc, Rockville, MD USA
[8] Sun Yat Sen Univ, State Key Lab Oncol South China Collaborat Innova, Canc Ctr, Guangzhou, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152235
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3730
引用
收藏
页码：3730 / +
页数：4
相关论文
共 50 条
  • [41] SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199) IN A PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Lu, P.
    Fleischmann, R.
    Curtis, C.
    Ignatenko, S.
    Desai, M.
    Wong, S. L.
    Grebe, K. M.
    Zeng, J.
    Medema, J.
    Stolzenbach, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 298 - 298
  • [42] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
    Lu, Peng
    Fleischmann, Roy
    Curtis, Craig
    Ignatenko, Stanislav
    Desai, Monali
    Wong, Shekman L.
    Grebe, Kristie M.
    Zeng, Jiewei
    Medema, Jeroen
    Stolzenbach, James
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
    Li, Caixia
    Wei, Jia
    Zhou, Keshu
    Liu, Peng
    Huang, He
    Li, Fei
    Cai, Qingqing
    Dong, Yujun
    Yang, Shenmiao
    Zhou, Hui
    Zhang, Xinyou
    Zhang, Lu
    Shi, Zaixing
    Liang, Zhiyu
    Wu, Binghao
    Wu, Depei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)
    Jamie, Cavanagh
    Baylon, Honorata Giongco
    Caguioa, Priscilla B.
    Davies, Faith E.
    Gharibo, Mecide
    Akinaga, Shiro
    Kurman, Michael R.
    Novak, Barbara A.
    Yong, Kwee L.
    BLOOD, 2013, 122 (21)
  • [45] Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study
    Karol, Seth E.
    Cooper, Todd M.
    Bittencourt, Henrique
    Gore, Lia
    O'Brien, Maureen M.
    Fraser, Christopher
    Gambart, Marion
    Cario, Gunnar
    Zwaan, Christian Michel
    Bourquin, Jean-Pierre
    Loh, Mignon L.
    Caron, Hubert
    Prine, Betty
    Salem, Ahmed Hamed
    Unnebrink, Kristina
    Tong, Bo
    Palenski, Tammy
    Place, Andrew E.
    BLOOD, 2019, 134
  • [46] Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    De Vos, Sven
    Flowers, Christopher
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan Hale
    Reid, Erin G.
    Cordero, Jaclyn
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Salem, Ahmed H.
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study
    Qi, J.
    Li, J.
    Xu, W.
    Zhao, X.
    Yin, Q.
    Li, Y.
    Xu, F.
    Huang, H.
    Li, J.
    Qian, W.
    Zhao, Q.
    Wang, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S596 - S596
  • [48] Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sandhu, Karamjeet S.
    Quy Huynh-Tran
    Cooper, Elise Elise
    Zhang, Jianying
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Thomas, Sandra
    Robbins, Marjorie
    Aribi, Ahmed
    Salhotra, Amandeep
    Mei, Mathew
    Cai, Ji-Lian
    Spielberger, Ricardo
    Koller, Paul
    Aldoss, Ibrahim
    Stein, Anthony
    Marcucci, Guido
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S276 - S276
  • [49] A Phase 1/2 Study of a ROR1-Targeting CART Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)
    Wang, Michael
    Johnson, Patrick Connor
    Yazji, Salim
    Katz, Yisrael
    Pietrofeso, Angela
    Robinson, James
    Mei, Matthew
    Frigault, Matthew J.
    Breitmeyer, James B.
    Jacobson, Caron A.
    BLOOD, 2024, 144 : 1743 - 1744
  • [50] A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
    Li, Caixia
    Wei, Jia
    Zhou, Keshu
    Liu, Peng
    Huang, He
    Li, Fei
    Dong, Yujun
    Cai, Qingqing
    Yang, Shenmiao
    Zhang, Xinyou
    Zhou, Hui
    Zhang, Lu
    Shi, Zaixing
    Liang, Zhiyu
    Wu, Binghao
    Wu, Depei
    BLOOD, 2022, 140 : 6717 - 6718
12345